Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
NCIC Clinical Trials Group
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00316836
First received: April 19, 2006
Last updated: May 9, 2009
Last verified: July 2008

April 19, 2006
May 9, 2009
April 2006
October 2010   (final data collection date for primary outcome measure)
  • Changes in breast density measured by percent and area at 1 and 2 years [ Designated as safety issue: No ]
  • Correlation of changes in breast density with plasma hormones and drug levels measured by estrone, estrone-sulfate, estradiol, sex hormone binding globulin, anastrozole, or exemestane levels at 1 and 2 years [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00316836 on ClinicalTrials.gov Archive Site
Correlation of breast density with contralateral breast cancers at 1 and 2 years [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27

RATIONALE: Understanding the relationship between breast density, levels of hormones in the blood, and levels of anticancer drugs in the blood may help improve the ability to plan effective treatment for women with invasive breast cancer.

PURPOSE: This clinical trial is studying the relationship between breast density and blood levels of hormones and anticancer drugs in women with invasive breast cancer who are receiving exemestane or anastrozole.

OBJECTIVES:

Primary

  • Assess the change in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year, 1 year to 2 years, and pretreatment to 2 years in women with invasive breast cancer.
  • Determine the changes in percent breast density and dense area in response to aromatase inhibitor therapy from pretreatment to 1 year and correlate the changes with changes in plasma hormones (e.g., estrone, estrone-sulfate, estradiol, and sex hormone binding globulin) and drug levels (anastrozole or exemestane) over the same period in women with invasive breast cancer.
  • Determine the change over time in percent breast density and dense area (from pretreatment to the time period prior to local recurrence) in the contralateral breast in correlation to local recurrence of breast cancer.

Secondary

  • Determine the change over time in percent breast density and dense area in the contralateral breast in correlation to the development of contralateral breast cancer.
  • Determine whether women with high pretreatment percent density (upper tertile) experience greater decreases in percent breast density at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment percent density (lower tertile).
  • Determine whether women with high pretreatment dense area (upper tertile) experience greater decreases in dense area at 1 and 2 years of aromatase inhibitor therapy than women with low pretreatment dense area (lower tertile).
  • Correlate haplotype tagged single nucleotide polymorphisms in genes in the aromatase pathway (identified thorough the Mayo Clinic and Indiana University Pharmacogenomics Research Network Projects) with changes in percent and area breast density, plasma hormone levels, and 1-year drug levels.

OUTLINE: This is a multicenter, companion study.

Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.

PROJECTED ACCRUAL: A total of 550 patients will be accrued for this study.

Interventional
Not Provided
Masking: Open Label
Primary Purpose: Diagnostic
Breast Cancer
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
  • Procedure: radiomammography
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
550
Not Provided
October 2010   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed invasive breast cancer
  • Completely resected disease
  • One intact, noncancerous breast with no prior breast surgery in that breast except breast biopsy

    • Mammogram available taken within 12 months prior to enrollment that includes side- and top-down views of the intact, noncancerous breast
  • Estrogen receptor- and/or progesterone receptor-positive tumor

PATIENT CHARACTERISTICS:

  • Female
  • Postmenopausal
  • Agrees to retrieve and digitize mammograms taken prior to registration (within 12 months prior to atudy entry) and at approximately 1 and 2 years post-registration to this study
  • Agrees to have an additional blood banking specimen drawn at the same time as pre-treatment specimens are drawn for parent protocol CAN-NCIC-MA27
  • Agrees to have blood sample taken at 12 months post-registration on this study

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • More than 6 months since prior hormone replacement therapy, oral contraceptives, tamoxifen, raloxifene, other selective estrogen-receptor modulators, or gonadotropin releasing-hormone analogues before pre-registration mammogram
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00316836
CDR0000462330, NCCTG-N0434, CAN-NCIC-MA27D
Not Provided
Not Provided
North Central Cancer Treatment Group
  • National Cancer Institute (NCI)
  • NCIC Clinical Trials Group
Study Chair: James N. Ingle, MD Mayo Clinic
Investigator: Celine M. Vachon, PhD Mayo Clinic
Investigator: Paul E. Goss, MD, PhD Massachusetts General Hospital
Investigator: Philip J. Stella, MD Ann Arbor Hematology Oncology Associates, PC at St. Joseph Mercy Cancer Center
Investigator: Kathleen I. Pritchard, MD Edmond Odette Cancer Centre at Sunnybrook
Study Chair: Kathleen I. Pritchard, MD Edmond Odette Cancer Centre at Sunnybrook
National Cancer Institute (NCI)
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP